Nektar Therapeutics Class Action Notice Issued
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy NKTR?
Source: Globenewswire
- Class Action Deadline: Purchasers of Nektar Therapeutics securities from February 26, 2025, to December 15, 2025, must be aware that the lead plaintiff deadline is May 5, 2026, after which they cannot participate in claims.
- Transparent Fee Structure: Participants can obtain compensation through a contingency fee arrangement without upfront costs, ensuring that investors do not bear additional financial burdens during the legal process, thereby lowering the barriers to participation.
- Law Firm Credentials: The Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, showcasing its strong capabilities and successful track record, which enhances investor confidence.
- Core Allegations: The lawsuit alleges that Nektar failed to follow applicable instructions and protocol standards in the REZOLVE-AA trial, raising concerns about the integrity of the trial results, which could lead to investor losses, highlighting the importance of corporate transparency and compliance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NKTR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NKTR
Wall Street analysts forecast NKTR stock price to rise
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 100.350
Low
102.00
Averages
123.43
High
165.00
Current: 100.350
Low
102.00
Averages
123.43
High
165.00
About NKTR
Nektar Therapeutics is a clinical-stage biotechnology company. It is focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel regulatory T cell stimulator being evaluated in two Phase IIb clinical trials, one in atopic dermatitis and one in alopecia areata. Its pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. It is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Nektar Therapeutics Prices $325 Million Upsized Public Offering
- Upsized Offering: Nektar Therapeutics announced the pricing of an upsized public offering of 3,532,609 shares at $92.00 per share, expected to generate approximately $325 million, providing substantial funding for its research and clinical trials.
- Clear Use of Proceeds: The net proceeds from this offering will be allocated for general corporate purposes, including supporting Phase 3 trials for rezpegaldesleukin in atopic dermatitis and alopecia areata, reflecting the company's commitment to its lead product and confidence in its market potential.
- Strong Underwriting Team: The offering is managed by a robust team including Jefferies, TD Cowen, and Piper Sandler, with Citigroup also participating, which is expected to enhance market confidence in the offering's success.
- Regulatory Compliance: This offering is conducted under an effective S-3ASR registration statement, ensuring compliance and transparency, with an expected closing date of April 23, 2026, further bolstering investor trust in Nektar.
See More
Nektar Therapeutics Prices $325 Million Upsized Public Offering
- Upsized Offering: Nektar Therapeutics announced the pricing of 3,532,609 shares at $92.00 each, raising approximately $325 million, reflecting strong market confidence in its immunotherapy products.
- Clear Use of Proceeds: The net proceeds will be allocated for general corporate purposes, including research and development, clinical trials (notably Phase 3 for atopic dermatitis and alopecia areata), and manufacturing costs, aimed at accelerating the advancement of its drug candidates.
- Strong Underwriter Support: Jefferies, TD Cowen, and Piper Sandler are acting as joint bookrunning managers for the offering, with Citigroup also participating, indicating robust investment banking support and market recognition for Nektar.
- Regulatory Compliance: The offering is made under an effective S-3ASR registration statement, ensuring compliance and streamlining the issuance process, with an expected closing date of April 23, 2026, enhancing the company's transparency in capital markets.
See More
Nektar Therapeutics Class Action Notice Issued
- Class Action Deadline: Purchasers of Nektar Therapeutics securities from February 26, 2025, to December 15, 2025, must be aware that the lead plaintiff deadline is May 5, 2026, after which they cannot participate in claims.
- Transparent Fee Structure: Participants can obtain compensation through a contingency fee arrangement without upfront costs, ensuring that investors do not bear additional financial burdens during the legal process, thereby lowering the barriers to participation.
- Law Firm Credentials: The Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, showcasing its strong capabilities and successful track record, which enhances investor confidence.
- Core Allegations: The lawsuit alleges that Nektar failed to follow applicable instructions and protocol standards in the REZOLVE-AA trial, raising concerns about the integrity of the trial results, which could lead to investor losses, highlighting the importance of corporate transparency and compliance.
See More
Class Action Lawsuits Filed Against Boston Scientific and Others
- Boston Scientific Lawsuit: A class action lawsuit against Boston Scientific Corporation (NYSE:BSX) alleges that from July 23, 2025, to February 3, 2026, the company failed to disclose that its U.S. electrophysiology segment's growth rate was unsustainable, which severely undermined investor confidence and is expected to negatively impact stock performance.
- Eos Energy Issues: Eos Energy Enterprises (NASDAQ:EOSE) faces a class action lawsuit for the period from November 5, 2025, to February 26, 2026, alleging that the company could not achieve necessary production ramp-up and that its battery line downtime exceeded industry norms, potentially leading to a decline in market share and investor trust.
- Soleno Therapeutics Risks: Soleno Therapeutics, Inc. (NASDAQ:SLNO) is accused in a class action lawsuit covering March 26, 2025, to November 4, 2025, of concealing significant safety concerns related to its DCCR clinical trial, which could materially affect its commercial viability and expose investors to legal and reputational risks.
- Nektar Therapeutics Trial Issues: Nektar Therapeutics (NASDAQ:NKTR) is implicated in a class action lawsuit for the period from February 26, 2025, to December 15, 2025, for failing to adhere to trial protocols in its REZOLVE-AA trial, likely compromising the trial's integrity and further eroding investor confidence in the company's future prospects.
See More
Faruqi & Faruqi Investigates Nektar Investor Losses
- Legal Investigation Launched: Faruq & Faruqi, LLP is investigating Nektar Therapeutics, Inc. for potential claims from investors who purchased securities between February 26, 2025, and December 15, 2025, indicating concerns about the company's financial health.
- Investor Rights Reminder: The firm reminds investors that May 5, 2026, is the deadline to seek the role of lead plaintiff in a federal securities class action, highlighting the urgency and significance of investor participation in legal proceedings.
- Direct Contact Channels: Investors can directly reach out to Faruq & Faruqi partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310), providing a convenient avenue for legal consultation.
- Potential Market Impact: This investigation may negatively affect Nektar's stock price, prompting investors to monitor subsequent legal developments to assess the risks and potential losses associated with their investments.
See More
Nektar Therapeutics' Hair Loss Drug Shows Promising Trial Results
- Clinical Trial Results: Nektar Therapeutics reported promising results from its phase 2b trial of rezpegaldesleukin for severe alopecia areata, showing hair growth over 52 weeks, which led to an 18.25% surge in stock price, reflecting strong market optimism.
- Strong Market Reaction: Following the trial results, Nektar's stock rose significantly to $15.49, with a market cap of $2.4 billion, indicating investor confidence in the drug's potential, especially after last year's disappointing trial outcomes.
- Drug Development Progress: Nektar announced plans to advance rezpegaldesleukin into later-stage trials, demonstrating increased confidence in the drug and aiming to validate its efficacy and safety through further research.
- Market Demand Potential: Alopecia areata affects millions in the U.S., and Nektar's innovative approach to treating this common autoimmune disorder highlights the drug's significant market potential, drawing considerable investor interest.
See More
Nektar Therapeutics Prices $325 Million Upsized Public Offering
- Upsized Offering: Nektar Therapeutics announced the pricing of an upsized public offering of 3,532,609 shares at $92.00 per share, expected to generate approximately $325 million, providing substantial funding for its research and clinical trials.
- Clear Use of Proceeds: The net proceeds from this offering will be allocated for general corporate purposes, including supporting Phase 3 trials for rezpegaldesleukin in atopic dermatitis and alopecia areata, reflecting the company's commitment to its lead product and confidence in its market potential.
- Strong Underwriting Team: The offering is managed by a robust team including Jefferies, TD Cowen, and Piper Sandler, with Citigroup also participating, which is expected to enhance market confidence in the offering's success.
- Regulatory Compliance: This offering is conducted under an effective S-3ASR registration statement, ensuring compliance and transparency, with an expected closing date of April 23, 2026, further bolstering investor trust in Nektar.
See More
Nektar Therapeutics Prices $325 Million Upsized Public Offering
- Upsized Offering: Nektar Therapeutics announced the pricing of 3,532,609 shares at $92.00 each, raising approximately $325 million, reflecting strong market confidence in its immunotherapy products.
- Clear Use of Proceeds: The net proceeds will be allocated for general corporate purposes, including research and development, clinical trials (notably Phase 3 for atopic dermatitis and alopecia areata), and manufacturing costs, aimed at accelerating the advancement of its drug candidates.
- Strong Underwriter Support: Jefferies, TD Cowen, and Piper Sandler are acting as joint bookrunning managers for the offering, with Citigroup also participating, indicating robust investment banking support and market recognition for Nektar.
- Regulatory Compliance: The offering is made under an effective S-3ASR registration statement, ensuring compliance and streamlining the issuance process, with an expected closing date of April 23, 2026, enhancing the company's transparency in capital markets.
See More
Nektar Therapeutics Class Action Notice Issued
- Class Action Deadline: Purchasers of Nektar Therapeutics securities from February 26, 2025, to December 15, 2025, must be aware that the lead plaintiff deadline is May 5, 2026, after which they cannot participate in claims.
- Transparent Fee Structure: Participants can obtain compensation through a contingency fee arrangement without upfront costs, ensuring that investors do not bear additional financial burdens during the legal process, thereby lowering the barriers to participation.
- Law Firm Credentials: The Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, showcasing its strong capabilities and successful track record, which enhances investor confidence.
- Core Allegations: The lawsuit alleges that Nektar failed to follow applicable instructions and protocol standards in the REZOLVE-AA trial, raising concerns about the integrity of the trial results, which could lead to investor losses, highlighting the importance of corporate transparency and compliance.
See More
Class Action Lawsuits Filed Against Boston Scientific and Others
- Boston Scientific Lawsuit: A class action lawsuit against Boston Scientific Corporation (NYSE:BSX) alleges that from July 23, 2025, to February 3, 2026, the company failed to disclose that its U.S. electrophysiology segment's growth rate was unsustainable, which severely undermined investor confidence and is expected to negatively impact stock performance.
- Eos Energy Issues: Eos Energy Enterprises (NASDAQ:EOSE) faces a class action lawsuit for the period from November 5, 2025, to February 26, 2026, alleging that the company could not achieve necessary production ramp-up and that its battery line downtime exceeded industry norms, potentially leading to a decline in market share and investor trust.
- Soleno Therapeutics Risks: Soleno Therapeutics, Inc. (NASDAQ:SLNO) is accused in a class action lawsuit covering March 26, 2025, to November 4, 2025, of concealing significant safety concerns related to its DCCR clinical trial, which could materially affect its commercial viability and expose investors to legal and reputational risks.
- Nektar Therapeutics Trial Issues: Nektar Therapeutics (NASDAQ:NKTR) is implicated in a class action lawsuit for the period from February 26, 2025, to December 15, 2025, for failing to adhere to trial protocols in its REZOLVE-AA trial, likely compromising the trial's integrity and further eroding investor confidence in the company's future prospects.
See More
Faruqi & Faruqi Investigates Nektar Investor Losses
- Legal Investigation Launched: Faruq & Faruqi, LLP is investigating Nektar Therapeutics, Inc. for potential claims from investors who purchased securities between February 26, 2025, and December 15, 2025, indicating concerns about the company's financial health.
- Investor Rights Reminder: The firm reminds investors that May 5, 2026, is the deadline to seek the role of lead plaintiff in a federal securities class action, highlighting the urgency and significance of investor participation in legal proceedings.
- Direct Contact Channels: Investors can directly reach out to Faruq & Faruqi partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310), providing a convenient avenue for legal consultation.
- Potential Market Impact: This investigation may negatively affect Nektar's stock price, prompting investors to monitor subsequent legal developments to assess the risks and potential losses associated with their investments.
See More
Nektar Therapeutics' Hair Loss Drug Shows Promising Trial Results
- Clinical Trial Results: Nektar Therapeutics reported promising results from its phase 2b trial of rezpegaldesleukin for severe alopecia areata, showing hair growth over 52 weeks, which led to an 18.25% surge in stock price, reflecting strong market optimism.
- Strong Market Reaction: Following the trial results, Nektar's stock rose significantly to $15.49, with a market cap of $2.4 billion, indicating investor confidence in the drug's potential, especially after last year's disappointing trial outcomes.
- Drug Development Progress: Nektar announced plans to advance rezpegaldesleukin into later-stage trials, demonstrating increased confidence in the drug and aiming to validate its efficacy and safety through further research.
- Market Demand Potential: Alopecia areata affects millions in the U.S., and Nektar's innovative approach to treating this common autoimmune disorder highlights the drug's significant market potential, drawing considerable investor interest.
See More
